Multi-omics analysis of serial samples from metastatic TNBC patients on PARP inhibitor monotherapy provide insight into rational PARP inhibitor therapy combinations
Authors:
- Marilyne LabrieMLMarilyne Labrie
- Allen LiALAllen Li
- Allison CreasonACAllison Creason
- Courtney BettsCBCourtney Betts
- Jamie KeckJKJamie Keck
- Brett JohnsonBJBrett Johnson
- Shamilene SivagnanamSSShamilene Sivagnanam
- Christopher BonifaceCBChristopher Boniface
- Hongli MaHMHongli Ma
- Aurora BlucherABAurora Blucher
- Young Hwan ChangYCYoung Hwan Chang
- Koei ChinKCKoei Chin
Preprint
Abstract
Due to complexity of advanced epithelial cancers, it is necessary to implement patient specific combination therapies if we are to markedly improve patient outcomes. However, our ability to select and implement patient specific combination therapies based on dynamic molecular changes in the tumor and tumor ecosystem in response to therapy remains extremely limited. In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Although PARP inhibition was consistently observed in all patients, deep molecular analysis of the tumor and its ecosystem revealed insights into potentially effective therapeutic PARPi combinations. In a BRCA-mutant basal breast cancer exceptional long-term survivor, we noted striking PARPi-induced tumor destruction accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor (LAR) rapid progressor in response to PARPi likely due to indifference to the effects of PARP inhibition. In this rapid progressor, there was minimal evidence of immune activation or protein network rewiring in response to PARPi, despite PARP being inhibited, and no clinical benefit was noted for this participant. Together, deep real-time analysis of longitudinal biopsies identified a suite of PARPi-induced emergent changes including immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK, that could be used to select patient specific combination therapies, based on tumor and immune state changes that are likely to benefit specific patients. Highlights: Longitudinal analysis of serial tumor samples in real-time identifies adaptive mechanisms of resistance to PARPi therapies. Deep molecular analysis of the tumor reveals insights into potentially effective therapeutic PARPi combinations. Extensive protein network rewiring, microenvironment and immune state changes are assessable factors for patient specific combination therapies.Keywords
All Related Versions
- Published version: npj Precision Oncology, 5 (1), 1.
This publication has 44 references indexed in Scilit:
- High-dimensional multiplexed immunohistochemical characterization of immune contexture in human cancers2020
- Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining EfficacyCancer Cell, 2019
- PARP inhibition enhances tumor cell–intrinsic immunity in ERCC1-deficient non–small cell lung cancerJournal of Clinical Investigation, 2019
- PARP Inhibition Elicits STING-Dependent Antitumor Immunity in Brca1-Deficient Ovarian CancerCell Reports, 2018
- Olaparib-induced Adaptive Response Is Disrupted by FOXM1 Targeting that Enhances Sensitivity to PARP InhibitionMolecular Cancer Research, 2018
- Combined BRAF, EGFR, and MEK Inhibition in Patients with BRAFV600E-Mutant Colorectal CancerCancer Discovery, 2018
- Abstract PD6-11: An open-label, multitumor, phase II basket study of olaparib and durvalumab (MEDIOLA): Results in germline BRCA-mutated (gBRCAm) HER2-negative metastatic breast cancer (MBC)Cancer Research, 2018
- Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer CellsPLOS ONE, 2016
- Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast CancerClinical Cancer Research, 2015
- A pan-cancer proteomic perspective on The Cancer Genome AtlasNature Communications, 2014